{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:59:33Z","timestamp":1770508773719,"version":"3.49.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,5,17]],"date-time":"2010-05-17T00:00:00Z","timestamp":1274054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1472-6963-10-128","type":"journal-article","created":{"date-parts":[[2012,6,29]],"date-time":"2012-06-29T12:16:16Z","timestamp":1340972176000},"source":"Crossref","is-referenced-by-count":56,"title":["Forecasting drug utilization and expenditure in a metropolitan health region"],"prefix":"10.1186","volume":"10","author":[{"name":"the Regional Drug Expert Consortium in Stockholm County Council","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Wettermark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie E","family":"Persson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Wilking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Kalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seher","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Hjemdahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Godman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Petzold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars L","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,17]]},"reference":[{"key":"1265_CR1","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.287.5460.1960","volume":"287","author":"J Drews","year":"2000","unstructured":"Drews J: Drug discovery: a historical perspective. Science. 2000, 287: 1960-4. 10.1126\/science.287.5460.1960.","journal-title":"Science"},{"key":"1265_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature02626","volume":"429","author":"WA Evans","year":"2004","unstructured":"Evans WA, Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature. 2004, 429: 464-8. 10.1038\/nature02626.","journal-title":"Nature"},{"key":"1265_CR3","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1517\/14656566.6.8.1299","volume":"6","author":"W Kalow","year":"2005","unstructured":"Kalow W: A pharmacogeneticist's look at drug effects and the drug development process: an overview. Exp Opin Pharmacother. 2005, 6: 1299-303. 10.1517\/14656566.6.8.1299.","journal-title":"Exp Opin Pharmacother"},{"key":"1265_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/sj.clpt.6100204","volume":"81","author":"LJ Lesko","year":"2007","unstructured":"Lesko LJ: Personalized medicine: elusive dream or imminent reality?. Clin Pharmacol Ther. 2007, 81: 807-16. 10.1038\/sj.clpt.6100204.","journal-title":"Clin Pharmacol Ther"},{"key":"1265_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrd2813","volume":"8","author":"B Hughes","year":"2009","unstructured":"Hughes B: 2008 FDA drug approvals. Nature reviews. 2009, 8: 93-96. 10.1038\/nrd2813.","journal-title":"Nature reviews"},{"key":"1265_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.healthpol.2007.08.005","volume":"85","author":"L Garattini","year":"2008","unstructured":"Garattini L, Motterlini N, Cornago D: Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries. Health Policy. 2008, 85: 305-13. 10.1016\/j.healthpol.2007.08.005.","journal-title":"Health Policy"},{"key":"1265_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMp0804261","volume":"359","author":"TH Lee","year":"2008","unstructured":"Lee TH, Emanuel EJ: Perspective. Tier 4 drugs and the fraying of the social compact. N Engl J Med. 2008, 359: 333-5. 10.1056\/NEJMp0804261.","journal-title":"N Engl J Med"},{"key":"1265_CR8","first-page":"2917","volume":"105","author":"LL Gustafsson","year":"2008","unstructured":"Gustafsson LL, Wettermark B, Kalin M, Korkmaz S, Persson M, Almkvist H, Hjemdahl P, Kristianson K, Ringertz B, Th\u00f6rnwall-Bergendahl G, Wilking N: Modell f\u00f6r strukturerad introduktion av nya l\u00e4kemedel: syftet \u00e4r att erbjuda alla patienter \u00e4ndam\u00e5lsenlig behandling. L\u00e4kartidningen. 2008, 105: 2917-22. (Model for structured introduction of new drugs: the aim is to offer all patients adequate treatment - in Swedish)","journal-title":"L\u00e4kartidningen"},{"key":"1265_CR9","volume-title":"Guidelines for ATC classification and DDD assignment. WHO Collaborationg Center for Drug Statistics Methodology, Oslo","author":"World Health Organization","year":"2008","unstructured":"World Health Organization: Guidelines for ATC classification and DDD assignment. WHO Collaborationg Center for Drug Statistics Methodology, Oslo. 2008, Accessed at July 30, 2008., [ http:\/\/www.whocc.no ]"},{"key":"1265_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1586\/14737167.9.1.65","volume":"9","author":"B Godman","year":"2009","unstructured":"Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL: Swedish experience in ambulatory care with multifaceted national and regional drug reforms and initiatives: global relevance. Expert Review of Pharmacoeconomics and Outcomes Research. 2009, 9: 65-83. 10.1586\/14737167.9.1.65.","journal-title":"Expert Review of Pharmacoeconomics and Outcomes Research"},{"key":"1265_CR11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.healthpol.2006.07.005","volume":"81","author":"K Andersson","year":"2007","unstructured":"Andersson K, Bergstr\u00f6m G, Petzold MG, Carlsten A: Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals. Health Policy. 2007, 81: 376-84. 10.1016\/j.healthpol.2006.07.005.","journal-title":"Health Policy"},{"key":"1265_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/annonc\/mdm345","volume":"19","author":"H Mellstedt","year":"2008","unstructured":"Mellstedt H, Niederwieser D, Ludwig H: The challenge of biosimilars. Ann Oncol. 2008, 19: 411-9. 10.1093\/annonc\/mdm345.","journal-title":"Ann Oncol"},{"key":"1265_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored M, Leimanis A, Otterblad-Olausson P, Bergman U, Persson I, Sundstr\u00f6m A, Westerholm B, Ros\u00e9n M: The new Swedish Prescribed Drug Register - Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007, 16: 726-35. 10.1002\/pds.1294.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1265_CR14","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.5694\/j.1326-5377.2004.tb05948.x","volume":"180","author":"R Grol","year":"2004","unstructured":"Grol R, Wensing M: What drives change? Barriers to and incentives for achieving evidence-based practice. Med J Aust. 2004, 180: S57-60.","journal-title":"Med J Aust"},{"key":"1265_CR15","first-page":"179","volume":"17","author":"B Wettermark","year":"2009","unstructured":"Wettermark B, Pehrsson \u00c5, Juhasz-Haverinen M, Veg M, Edlert M, T\u00f6rnwall-Bergendahl G, Almqvist M, Godman B, Bergman U: Financial incentives linked to self-assessment of prescribing patterns - a new approach for quality improvement of drug prescribing in primary care. Quality in Primary Care. 2009, 17: 179-89.","journal-title":"Quality in Primary Care"},{"key":"1265_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1017\/S0266462307070493","volume":"23","author":"K Murphy","year":"2007","unstructured":"Murphy K, Packer C, Stevens A, Simpson S: Effective early warning systems for new and emerging health technologies: developing an evaluation framework and an assessment of current systems. Int J Technol Assess Health Care. 2007, 23: 324-30. 10.1017\/S0266462307070493.","journal-title":"Int J Technol Assess Health Care"},{"key":"1265_CR17","volume-title":"Diabetes atlas","author":"International Diabetes Federation","year":"2008","unstructured":"International Diabetes Federation: Diabetes atlas. 2008, Brussels: International Diabetes Federation, 3","edition":"3"},{"key":"1265_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/dtb.2008.06.0014","volume":"46","author":"Anonymous","year":"2008","unstructured":"Anonymous: Three new drugs for type 2 diabetes. Drug Ther Bull. 2008, 46: 49-52. 10.1136\/dtb.2008.06.0014.","journal-title":"Drug Ther Bull"},{"key":"1265_CR19","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007, 356: 2457-71. 10.1056\/NEJMoa072761.","journal-title":"N Engl J Med"},{"key":"1265_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.298.2.194","volume":"298","author":"E Amori","year":"2007","unstructured":"Amori E, Lau J, Pittas A: Efficacy and safety of incretin therapy in type 2 diabetes. JAMA. 2007, 298: 194-206. 10.1001\/jama.298.2.194.","journal-title":"JAMA"},{"key":"1265_CR21","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00125-009-1444-2","volume":"52","author":"JM Jonassson","year":"2009","unstructured":"Jonassson JM, Ljung R, Talb\u00e4ck M, Haglund B, Gudbj\u00f6rnsd\u00f2ttir S, Steineck G: Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologica. 2009, 52: 1745-54. 10.1007\/s00125-009-1444-2.","journal-title":"Diabetologica"},{"issue":"5","key":"1265_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1365-2125.2009.03369.x","volume":"67","author":"R Joppi","year":"2009","unstructured":"Joppi R, Bertele' V, Garattini S: Orphan drug development is not taking off. Br J Clin Pharmacol. 2009, 67 (5): 494-502. 10.1111\/j.1365-2125.2009.03369.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1265_CR23","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2165\/00003495-200666110-00001","volume":"66","author":"BI Eriksson","year":"2006","unstructured":"Eriksson BI, Quinlan DJ: Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs. 2006, 66: 1411-29. 10.2165\/00003495-200666110-00001.","journal-title":"Drugs"},{"key":"1265_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/eurheartj\/ehm575","volume":"29","author":"AG Turpie","year":"2008","unstructured":"Turpie AG: New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008, 29: 155-65. 10.1093\/eurheartj\/ehm575.","journal-title":"Eur Heart J"},{"key":"1265_CR25","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361: 1139-51. 10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"key":"1265_CR26","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/S0195-668X(03)00347-6","volume":"24","author":"G De Backer","year":"2003","unstructured":"De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gom\u00e9r K, Perk J, Py\u00f6r\u00e4l\u00e4 K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, Third joint task force of European and other societies on cardiovascular disease prevention in Clinical Practice: European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003, 24: 1601-10. 10.1016\/S0195-668X(03)00347-6.","journal-title":"Eur Heart J"},{"key":"1265_CR27","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thors\u00e9n M: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009, 361: 1045-57. 10.1056\/NEJMoa0904327.","journal-title":"N Engl J Med"},{"key":"1265_CR28","volume-title":"A review of medicines for lowering blood pressure - A summary","author":"N Hedberg","year":"2008","unstructured":"Hedberg N, Jacob J: A review of medicines for lowering blood pressure - A summary. 2008, Solna: Dental and Pharmaceutical Benefits Agency, [Accessed 17 April 10], [ http:\/\/www.tlv.se\/Upload\/Genomgangen\/review-blood-pressure.pdf ]"},{"key":"1265_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.healthpol.2009.09.014","volume":"94","author":"B Wettermark","year":"2010","unstructured":"Wettermark B, Godman B, Hedberg N, Mellgren T-O, Neovius M, Kahan T: Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy. 2010, 94: 221-9. 10.1016\/j.healthpol.2009.09.014.","journal-title":"Health Policy"},{"key":"1265_CR30","volume-title":"The review of medicines for treating lipid disorders - A summary","author":"G Eriksson","year":"2009","unstructured":"Eriksson G, Lundin D: The review of medicines for treating lipid disorders - A summary. 2009, Solna: Dental and Pharmaceutical Benefits Agency, [Accessed 24 April 09], [ http:\/\/www.tlv.se\/Upload\/Genomgangen\/summary-lipids.pdf ]"},{"key":"1265_CR31","doi-asserted-by":"publisher","first-page":"520","DOI":"10.7326\/0003-4819-145-7-200610030-00010","volume":"145","author":"RA Hayward","year":"2006","unstructured":"Hayward RA, Hofer TP, Vijan S: Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006, 145: 520-30.","journal-title":"Ann Intern Med"},{"key":"1265_CR32","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1056\/NEJMoa0803778","volume":"360","author":"SH Hohnloser","year":"2009","unstructured":"Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ, ATHENA Investigators: Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009, 360: 668-78. 10.1056\/NEJMoa0803778.","journal-title":"N Engl J Med"},{"key":"1265_CR33","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMp0902248","volume":"360","author":"PJ Zimetbaum","year":"2009","unstructured":"Zimetbaum PJ: Dronedarone for atrial fibrillation--an odyssey. N Engl J Med. 2009, 360: 1811-3. 10.1056\/NEJMp0902248.","journal-title":"N Engl J Med"},{"key":"1265_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/jama.288.1.49","volume":"288","author":"D Grady","year":"2002","unstructured":"Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N, HERS Research Group: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II). JAMA. 2002, 288: 49-57. 10.1001\/jama.288.1.49.","journal-title":"JAMA"},{"key":"1265_CR35","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-33. 10.1001\/jama.288.3.321.","journal-title":"JAMA"},{"key":"1265_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2147\/tcrm.2007.3.2.277","volume":"3","author":"M Kendirci","year":"2007","unstructured":"Kendirci M, Salem E, Hellstrom WJ: Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation. Ther Clin Risk Manag. 2007, 3: 277-89. 10.2147\/tcrm.2007.3.2.277.","journal-title":"Ther Clin Risk Manag"},{"key":"1265_CR37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1017\/S0266462306051336","volume":"22","author":"C Packer","year":"2006","unstructured":"Packer C, Simpson S, Stevens A, EuroScan: the European Information Network on New and Changing Health Technologies: International diffusion of new health technologies: a ten-country analysis of six health technologies. Int J Technol Assess Health Care. 2006, 22: 419-28. 10.1017\/S0266462306051336.","journal-title":"Int J Technol Assess Health Care"},{"key":"1265_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1377\/hlthaff.21.6.177","volume":"21","author":"R Klein","year":"2002","unstructured":"Klein R, Sturm H: Viagra: a success story for rationing?. Health Aff (Millwood). 2002, 21: 177-87. 10.1377\/hlthaff.21.6.177.","journal-title":"Health Aff (Millwood)"},{"issue":"Suppl 3","key":"1265_CR39","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/01.aids.0000327510.68503.e8","volume":"22","author":"TC Quinn","year":"2008","unstructured":"Quinn TC: HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS. 2008, 22 (Suppl 3): S7-12. 10.1097\/01.aids.0000327510.68503.e8.","journal-title":"AIDS"},{"key":"1265_CR40","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.2165\/00003495-200565130-00002","volume":"65","author":"JD Reeves","year":"2005","unstructured":"Reeves JD, Piefer AJ: Emerging drug targets for antiretroviral therapy. Drugs. 2005, 65: 1747-66. 10.2165\/00003495-200565130-00002.","journal-title":"Drugs"},{"key":"1265_CR41","volume-title":"Rekommendation f\u00f6r screening av patientgrupper som f\u00e5tt blodtransfusion i Sverige f\u00f6re 1992. (Recommendation about screening of patients receiving blood transfusions in Sweden before 1992, In Swedish)","author":"National Board of Health and Welfare","year":"2007","unstructured":"National Board of Health and Welfare: Rekommendation f\u00f6r screening av patientgrupper som f\u00e5tt blodtransfusion i Sverige f\u00f6re 1992. (Recommendation about screening of patients receiving blood transfusions in Sweden before 1992, In Swedish). 2007, Stockholm, Socialstyrelsen"},{"key":"1265_CR42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/pgmj.2008.068205","volume":"84","author":"TJ Cross","year":"2008","unstructured":"Cross TJ, Antoniades CG, Harrison PM: Current and future management of chronic hepatitis C infection. Postgrad Med J. 2008, 84: 172-6. 10.1136\/pgmj.2008.068205.","journal-title":"Postgrad Med J"},{"key":"1265_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/MJT.0b013e318155a191","volume":"15","author":"E Palumbo","year":"2008","unstructured":"Palumbo E: New drugs for chronic hepatitis B: a review. Am J Ther. 2008, 15: 167-72. 10.1097\/MJT.0b013e318155a191.","journal-title":"Am J Ther"},{"key":"1265_CR44","unstructured":"Struwe J, Olsson-Liljequist B, editors.: SWEDRES|2008 - A Report on Swedish Antimicrobial Utilisation and Resistance in Human Medicine. Swedish Strategic Programme against Antibiotic Resistance (STRAMA). 2008, Swedish Institute for Infectious Disease Control. Stockholm"},{"key":"1265_CR45","volume-title":"Nedre urinv\u00e4gsinfektion hos kvinnor. [Management of lower urinary tract infections in women]","author":"Medical Products Agency","year":"2007","unstructured":"Medical Products Agency: Nedre urinv\u00e4gsinfektion hos kvinnor. [Management of lower urinary tract infections in women]. 2007, Stockholm: Medical Products Agency, [In Swedish]."},{"key":"1265_CR46","doi-asserted-by":"crossref","unstructured":"Jansen AG, Hak E, Veenhoven RH, Damoiseaux RA, Schilder PLEAAG, Sanders EA: Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database Syst Rev. 2009, CD001480-2","DOI":"10.1002\/14651858.CD001480.pub3"},{"key":"1265_CR47","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/MOP.0b013e328305e298","volume":"20","author":"R Fisher","year":"2008","unstructured":"Fisher R, Darrow DH, Tranter M, Williams JV: Human papillomavirus vaccine: recommendations, issues and controversies. Curr Opin Pediatr. 2008, 20: 441-5. 10.1097\/MOP.0b013e328305e298.","journal-title":"Curr Opin Pediatr"},{"key":"1265_CR48","volume-title":"Economic consequences to society of pandemic H1N1 influenza 2009 - preliminary results for Sweden","author":"L Brouwers","year":"2009","unstructured":"Brouwers L, Cakici B, Camitz M, Tegnell A, Boman M: Economic consequences to society of pandemic H1N1 influenza 2009 - preliminary results for Sweden. Euro Surveill. 2009, 14 (37): pii: 19333"},{"key":"1265_CR49","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-717. 10.1016\/S0140-6736(05)66544-0.","journal-title":"Lancet"},{"key":"1265_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(08)60069-0","volume":"371","author":"M Clarke","year":"2008","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard KI, Wood WC: Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008, 371: 29-40. 10.1016\/S0140-6736(08)60069-0.","journal-title":"Lancet"},{"key":"1265_CR51","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"25","author":"JS Ross","year":"2009","unstructured":"Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. Oncologist. 2009, 25: 320-68. 10.1634\/theoncologist.2008-0230.","journal-title":"Oncologist"},{"key":"1265_CR52","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.2006.09.6081","volume":"25","author":"NJ Meropol","year":"2007","unstructured":"Meropol NJ, Schulman KA: Cost of cancer care: issues and implications. J Clin Oncol. 2007, 25: 180-6. 10.1200\/JCO.2006.09.6081.","journal-title":"J Clin Oncol"},{"key":"1265_CR53","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/j.1365-2036.2008.03684.x","volume":"27","author":"T Yau","year":"2008","unstructured":"Yau T, Chan P, Ching Chan Y, Wong BC, Liang R, Epstein RJ: Review article: current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies. Aliment Pharmacol Ther. 2008, 27: 997-1005. 10.1111\/j.1365-2036.2008.03684.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"1265_CR54","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.2174\/092986708786848578","volume":"15","author":"J Gora-Tybor","year":"2008","unstructured":"Gora-Tybor J, Robak T: Targeted drugs in chronic myeloid leukemia. Curr Med Chem. 2008, 15: 3036-51. 10.2174\/092986708786848578.","journal-title":"Curr Med Chem"},{"key":"1265_CR55","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/SPC.0b013e3283090475","volume":"2","author":"JR Berenson","year":"2008","unstructured":"Berenson JR, Yellin O: New drugs in multiple myeloma. Curr Opin Support Palliat Care. 2008, 2: 204-10. 10.1097\/SPC.0b013e3283090475.","journal-title":"Curr Opin Support Palliat Care"},{"key":"1265_CR56","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1517\/14740330902750114","volume":"8","author":"MC Winter","year":"2009","unstructured":"Winter MC, Hancock BW: Ten years of rituximab in NHL. Expert Opin Drug Saf. 2009, 8: 223-35. 10.1517\/14740330902750114.","journal-title":"Expert Opin Drug Saf"},{"key":"1265_CR57","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.ejca.2009.01.035","volume":"45","author":"B Jonsson","year":"2009","unstructured":"Jonsson B: Being NICE is not the problem!. Eur J Cancer. 2009, 45: 1100-2. 10.1016\/j.ejca.2009.01.035.","journal-title":"Eur J Cancer"},{"key":"1265_CR58","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.autrev.2005.04.016","volume":"4","author":"F Puppo","year":"2005","unstructured":"Puppo F, Murdaca G, Ghio M, Indiveri F: Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev. 2005, 4: 537-41. 10.1016\/j.autrev.2005.04.016.","journal-title":"Autoimmun Rev"},{"key":"1265_CR59","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/j.1526-4610.2008.01214.x","volume":"48","author":"SJ Tepper","year":"2008","unstructured":"Tepper SJ, Stillman MJ: Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine. Headache. 2008, 48: 1259-68. 10.1111\/j.1526-4610.2008.01214.x.","journal-title":"Headache"},{"key":"1265_CR60","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.nurt.2006.10.003","volume":"4","author":"AB Ettinger","year":"2007","unstructured":"Ettinger AB, Argoff CE: Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics. 2007, 4: 75-83. 10.1016\/j.nurt.2006.10.003.","journal-title":"Neurotherapeutics"},{"key":"1265_CR61","unstructured":"European Medicines Agency: Questions and answers on recommendation for refusal of a change to the marketing authorisation for Lyrica. [Accessed 5 October 09], [ http:\/\/www.emea.europa.eu\/pdfs\/human\/opinion\/LyricaQ&A_23113109en.pdf ]"},{"key":"1265_CR62","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1377\/hlthaff.26.2.450","volume":"26","author":"RM Scheffler","year":"2007","unstructured":"Scheffler RM, Hinshaw SP, Modrek S, Levine P: The global market for ADHD medications. Health Aff (Millwood). 2007, 26: 450-7. 10.1377\/hlthaff.26.2.450.","journal-title":"Health Aff (Millwood)"},{"key":"1265_CR63","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1755-3768.2007.00979.x","volume":"85","author":"UM Schmidt-Erfurth","year":"2007","unstructured":"Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corc\u00f2stegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann RO, European Society for Retina Specialists' Guidelines Committee (EURETINA): Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007, 85: 486-94. 10.1111\/j.1755-3768.2007.00979.x.","journal-title":"Acta Ophthalmol Scand"},{"key":"1265_CR64","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2146\/ajhp070629","volume":"65","author":"JM Hoffman","year":"2008","unstructured":"Hoffman JM, Shah ND, Vermeulen LC, Doloresco F, Grim P, Hunkler RJ, Hontz KM, Schumock GT: Projecting future drug expenditures--2008. Am J Health Syst Pharm. 2008, 65: 234-53. 10.2146\/ajhp070629.","journal-title":"Am J Health Syst Pharm"},{"key":"1265_CR65","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2146\/ajhp080636","volume":"66","author":"JM Hoffman","year":"2009","unstructured":"Hoffman JM, Shah ND, Vermeulen LC, Doloresco F, Martin PK, Blake S, Matusiak L, Hunkler RJ, Schumock GT: Projecting future drug expenditures-2009. Am J Health Syst Pharm. 2009, 66: 237-57. 10.2146\/ajhp080636.","journal-title":"Am J Health Syst Pharm"},{"key":"1265_CR66","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1377\/hlthaff.2009.1074","volume":"29","author":"CJ Truffer","year":"2010","unstructured":"Truffer CJ, Keehan S, Smith S, Cylus J, Sisko A, Poisal JA, Lizonitz J, Clemens MK: Health spending projections through 2019: the recession's impact continues. Health Aff (Millwood). 2010, 29: 522-9. 10.1377\/hlthaff.2009.1074.","journal-title":"Health Aff (Millwood)"},{"key":"1265_CR67","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1377\/hlthaff.27.1.14","volume":"27","author":"A Catlin","year":"2008","unstructured":"Catlin A, Cowan C, Hartman M, Heffler S, National Health Expenditure Accounts Team: National health spending in 2006: a year of change for prescription drugs. Health Aff (Millwood). 2008, 27: 14-29. 10.1377\/hlthaff.27.1.14.","journal-title":"Health Aff (Millwood)"},{"key":"1265_CR68","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJMp078020","volume":"356","author":"DM Cutler","year":"2007","unstructured":"Cutler DM: The demise of the blockbuster?. N Engl J Med. 2007, 356: 1292-3. 10.1056\/NEJMp078020.","journal-title":"N Engl J Med"},{"key":"1265_CR69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/445013a","volume":"445","author":"M Wadman","year":"2007","unstructured":"Wadman M: When the party's over. Nature. 2007, 445: 13-10.1038\/445013a.","journal-title":"Nature"},{"key":"1265_CR70","volume-title":"Financial incentives and prescribing in Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality","author":"T Walley","year":"2004","unstructured":"Walley T, Mossialos E: Financial incentives and prescribing in Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Edited by: Elias Mossialos, Monique Mrazek, Tom Walley. 2004, Open University Press, ISBN 0 335 21465 7(pb) 0 335 21466 5 (hb)"},{"key":"1265_CR71","doi-asserted-by":"crossref","unstructured":"Sturm H, Austvoll-Dahlgren A, Aaserud M, Oxman AD, Ramsay C, Vernby A, K\u00f6sters JP: Pharmaceutical policies: effects of financial incentives for prescribers (Review). Cochrane database of Systematic Reviews. 2007, CD006731-DOI: 10.1002\/14651858.CD006731, 3","DOI":"10.1002\/14651858.CD006731"},{"key":"1265_CR72","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00148365-200504020-00005","volume":"4","author":"AR Mason","year":"2005","unstructured":"Mason AR, Drummond MF, Hunter JA, Towse AK, Cooke J: Prescribing incentive schemes: a useful approach?. Appl Health Econ Health Policy. 2005, 4: 111-7. 10.2165\/00148365-200504020-00005.","journal-title":"Appl Health Econ Health Policy"},{"key":"1265_CR73","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/bmj.326.7400.1171","volume":"326","author":"H Melander","year":"2003","unstructured":"Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B: Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003, 326: 1171-3. 10.1136\/bmj.326.7400.1171.","journal-title":"BMJ"},{"issue":"3","key":"1265_CR74","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1017\/S0266462304001229","volume":"20","author":"S Simpson","year":"2004","unstructured":"Simpson S, Hyde C, Cook A, Packer C, Stevens A: Assessing the accuracy of forecasting: applying standard diagnostic assessment tools to a health technology early warning system. Int J Technol Assess Health Care. 2004, 20 (3): 381-4. 10.1017\/S0266462304001229.","journal-title":"Int J Technol Assess Health Care"},{"key":"1265_CR75","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.294.16.2075","volume":"294","author":"JH Barton","year":"2005","unstructured":"Barton JH, Emanuel EJ: The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA. 2005, 294: 2075-82. 10.1001\/jama.294.16.2075.","journal-title":"JAMA"},{"key":"1265_CR76","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0140-6736(09)61370-2","volume":"374","author":"A den Exter","year":"2009","unstructured":"den Exter A: European Commission takes on Big Pharma. Lancet. 2009, 374: 599-600. 10.1016\/S0140-6736(09)61370-2.","journal-title":"Lancet"},{"key":"1265_CR77","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00228-008-0537-z","volume":"64","author":"S Garattini","year":"2008","unstructured":"Garattini S, Bertel\u00e9 V, Godman B, Haycox A, Wettermark B, Gustafsson LL, The Piperska Group: Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol. 2008, 64: 1137-8. 10.1007\/s00228-008-0537-z.","journal-title":"Eur J Clin Pharmacol"},{"key":"1265_CR78","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1136\/ard.2005.045872","volume":"65","author":"J Askling","year":"2006","unstructured":"Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N, Lindblad S, Klareskog L: Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis. 2006, 65: 707-12. 10.1136\/ard.2005.045872.","journal-title":"Ann Rheum Dis"},{"key":"1265_CR79","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10754-005-6601-7","volume":"5","author":"FR Lichtenberg","year":"2005","unstructured":"Lichtenberg FR: The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001. Int J Health Care Finance Econ. 2005, 5: 47-73. 10.1007\/s10754-005-6601-7.","journal-title":"Int J Health Care Finance Econ"},{"key":"1265_CR80","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/hec.1382","volume":"18","author":"FR Lichtenberg","year":"2009","unstructured":"Lichtenberg FR: Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003. Health Econ. 2009, 18: 519-34. 10.1002\/hec.1382.","journal-title":"Health Econ"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6963-10-128\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-10-128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-10-128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-10-128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T23:32:38Z","timestamp":1594337558000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/1472-6963-10-128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,17]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1186\/1472-6963-10-128","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,17]]},"article-number":"128"}}